Quarterly Result26 Oct 2026, 05:21 pm
Astec Lifesciences Approves Q2 FY27 Unaudited Financial Results
AI Summary
Astec Lifesciences Limited announced the approval of its Unaudited Financial Results (Standalone & Consolidated) for the Quarter and Half Year ended September 30, 2026. The Board of Directors also noted the unmodified Limited Review Reports from the Statutory Auditors. The results were prepared as per Indian Accounting Standards (IND AS). The company reported total income of ₹7,263.64 Lakhs for the quarter ended September 30, 2026, compared to ₹7,483.62 Lakhs in the same period last year. For the half-year ended September 30, 2026, total income stood at ₹15,692.81 Lakhs.
Key Highlights
- Board approved unaudited financial results for Q2 FY27.
- Standalone and consolidated results were approved.
- Statutory Auditors provided unmodified review reports.
- Results prepared as per Indian Accounting Standards (IND AS).
- Total income for the quarter was ₹7,263.64 Lakhs.
Price Impact
More from ASTEC